NutrigeneAI was selected as a finalist at the “Baidao Converges Innovation” Medical–Engineering Integration and Industry Innovation Roundtable, alongside the 2025 Greater Bay Area Healthcare Innovation and Entrepreneurship Competition Finals, held on December 19, 2025, in Guangzhou. The company advanced to the Top 12 finals with its project “iPSC Therapies in Clinical Translation”, presented by CEO Bill, and was awarded the Outstanding Innovation Project distinction.
The event brought together stakeholders from government, industry, academia, research, healthcare, and investment sectors to highlight innovation and translational pathways in the Greater Bay Area life sciences ecosystem. Finalist projects were evaluated on clinical value, regulatory and registration strategies, technical validation, and commercialization feasibility. Driven by unmet needs in ischemic diseases such as PAD, CAD, and stroke, NutrigeneAI presented a QbD- and CMC-oriented translational strategy integrated with AI-enabled R&D acceleration, gaining constructive expert feedback and access to collaboration opportunities.
